Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 290

1.

Drug resistance and optimizing dolutegravir regimens for adolescents and young adults failing antiretroviral therapy.

Kouamou V, Manasa J, Katzenstein D, McGregor AM, Ndhlovu CE, Makadzange AT.

AIDS. 2019 Sep 1;33(11):1729-1737. doi: 10.1097/QAD.0000000000002284.

PMID:
31361272
2.

Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naive Adults in South Africa, 2000-2016: A Pooled Sequence Analysis.

Chimukangara B, Lessells RJ, Rhee SY, Giandhari J, Kharsany ABM, Naidoo K, Lewis L, Cawood C, Khanyile D, Ayalew KA, Diallo K, Samuel R, Hunt G, Vandormael A, Stray-Pedersen B, Gordon M, Makadzange T, Kiepiela P, Ramjee G, Ledwaba J, Kalimashe M, Morris L, Parikh UM, Mellors JW, Shafer RW, Katzenstein D, Moodley P, Gupta RK, Pillay D, Abdool Karim SS, de Oliveira T.

EClinicalMedicine. 2019 Mar 18;9:26-34. doi: 10.1016/j.eclinm.2019.03.006. eCollection 2019 Mar.

3.

Community-based self-collected human papillomavirus screening in rural Zimbabwe.

Fitzpatrick MB, El-Khatib Z, Katzenstein D, Pinsky BA, Chirenje ZM, McCarty K.

BMC Public Health. 2019 May 29;19(Suppl 1):603. doi: 10.1186/s12889-019-6810-5.

4.

Persistence of Human Immunodeficiency Virus-1 Drug Resistance Mutations in Proviral Deoxyribonucleic Acid After Virologic Failure of Efavirenz-Containing Antiretroviral Regimens.

De La Cruz J, Vardhanbhuti S, Sahoo MK, Rovner R, Bosch RJ, Manasa J, Katzenstein DA, Pinsky BA.

Open Forum Infect Dis. 2019 Jan 16;6(3):ofz034. doi: 10.1093/ofid/ofz034. eCollection 2019 Mar.

5.

hrHPV prevalence and type distribution in rural Zimbabwe: A community-based self-collection study using near-point-of-care GeneXpert HPV testing.

Fitzpatrick MB, Dube Mandishora RS, Katzenstein DA, McCarty K, Weber J, Sahoo MK, Manasa J, Chirenje ZM, Pinsky BA.

Int J Infect Dis. 2019 May;82:21-29. doi: 10.1016/j.ijid.2019.02.022. Epub 2019 Feb 23.

6.

Combining Phylogenetic and Network Approaches to Identify HIV-1 Transmission Links in San Mateo County, California.

Dalai SC, Junqueira DM, Wilkinson E, Mehra R, Kosakovsky Pond SL, Levy V, Israelski D, de Oliveira T, Katzenstein D.

Front Microbiol. 2018 Dec 6;9:2799. doi: 10.3389/fmicb.2018.02799. eCollection 2018.

7.

Patterns of detectable viraemia among children and adults with HIV infection taking antiretroviral therapy in Zimbabwe.

Sovershaeva E, Shamu T, Wilsgaard T, Bandason T, Flægstad T, Katzenstein D, Ferrand RA, Odland J.

Int J Infect Dis. 2019 Jan;78:65-71. doi: 10.1016/j.ijid.2018.10.019. Epub 2018 Oct 31.

8.

HIV-1 Drug Resistance and Third-Line Therapy Outcomes in Patients Failing Second-Line Therapy in Zimbabwe.

Chimbetete C, Katzenstein D, Shamu T, Spoerri A, Estill J, Egger M, Keiser O.

Open Forum Infect Dis. 2018 Feb 2;5(2):ofy005. doi: 10.1093/ofid/ofy005. eCollection 2018 Feb.

9.

Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors.

Manasa J, Varghese V, Pond SLK, Rhee SY, Tzou PL, Fessel WJ, Jang KS, White E, Rögnvaldsson T, Katzenstein DA, Shafer RW.

Sci Rep. 2017 Sep 14;7(1):11559. doi: 10.1038/s41598-017-11893-8.

10.

Community Based Antiretroviral Treatment in Rural Zimbabwe.

Chimukangara B, Manasa J, Mitchell R, Nyabadza G, Katzenstein D, Masimirembwa C.

AIDS Res Hum Retroviruses. 2017 Dec;33(12):1185-1191. doi: 10.1089/aid.2017.0029. Epub 2017 Oct 26.

PMID:
28899102
11.

Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation.

Paredes R, Tzou PL, van Zyl G, Barrow G, Camacho R, Carmona S, Grant PM, Gupta RK, Hamers RL, Harrigan PR, Jordan MR, Kantor R, Katzenstein DA, Kuritzkes DR, Maldarelli F, Otelea D, Wallis CL, Schapiro JM, Shafer RW.

PLoS One. 2017 Jul 28;12(7):e0181357. doi: 10.1371/journal.pone.0181357. eCollection 2017.

12.

Twice Silenced: The Underreporting of Child Sexual Abuse in Orthodox Jewish Communities.

Katzenstein D, Fontes LA.

J Child Sex Abus. 2017 Aug-Sep;26(6):752-767. doi: 10.1080/10538712.2017.1336505. Epub 2017 Jul 17.

PMID:
28715275
13.

Defining a Cutoff for Atazanavir in Hair Samples Associated With Virological Failure Among Adolescents Failing Second-Line Antiretroviral Treatment.

Chawana TD, Gandhi M, Nathoo K, Ngara B, Louie A, Horng H, Katzenstein D, Metcalfe J, Nhachi CFB; Adolescent Treatment Failure (ATF) study team.

J Acquir Immune Defic Syndr. 2017 Sep 1;76(1):55-59. doi: 10.1097/QAI.0000000000001452.

14.

A Simple Phosphate-Buffered-Saline-Based Extraction Method Improves Specificity of HIV Viral Load Monitoring Using Dried Blood Spots.

Makadzange AT, Boyd FK, Chimukangara B, Masimirembwa C, Katzenstein D, Ndhlovu CE.

J Clin Microbiol. 2017 Jul;55(7):2172-2179. doi: 10.1128/JCM.00176-17. Epub 2017 May 3.

15.

HIV drug resistance testing among patients failing second line antiretroviral therapy. Comparison of in-house and commercial sequencing.

Chimukangara B, Varyani B, Shamu T, Mutsvangwa J, Manasa J, White E, Chimbetete C, Luethy R, Katzenstein D.

J Virol Methods. 2017 May;243:151-157. doi: 10.1016/j.jviromet.2016.11.010. Epub 2016 Nov 25.

16.

Human Immunodeficiency Virus-1 Sequence Changes and Drug Resistance Mutation Among Virologic Failures of Lopinavir/Ritonavir Monotherapy: AIDS Clinical Trials Group Protocol A5230.

Vardhanabhuti S, Katzenstein D, Bartlett J, Kumarasamy N, Wallis CL.

Open Forum Infect Dis. 2016 Aug 24;3(3):ofw154. eCollection 2016 Sep.

17.

Evaluation of the Aptima HIV-1 Quant Dx Assay Using Plasma and Dried Blood Spots.

Sahoo MK, Varghese V, White E, Winslow M, Katzenstein DA, Shafer RW, Pinsky BA.

J Clin Microbiol. 2016 Oct;54(10):2597-601. doi: 10.1128/JCM.01569-16. Epub 2016 Aug 17.

18.

Global Comparison of Drug Resistance Mutations After First-Line Antiretroviral Therapy Across Human Immunodeficiency Virus-1 Subtypes.

Huang A, Hogan JW, Luo X, DeLong A, Saravanan S, Wu Y, Sirivichayakul S, Kumarasamy N, Zhang F, Phanuphak P, Diero L, Buziba N, Istrail S, Katzenstein DA, Kantor R.

Open Forum Infect Dis. 2015 Nov 3;3(2):ofv158. doi: 10.1093/ofid/ofv158. eCollection 2016 Apr.

19.

Transmitted HIV Drug Resistance Is High and Longstanding in Metropolitan Washington, DC.

Kassaye SG, Grossman Z, Balamane M, Johnston-White B, Liu C, Kumar P, Young M, Sneller MC, Sereti I, Dewar R, Rehm C, Meyer W 3rd, Shafer R, Katzenstein D, Maldarelli F.

Clin Infect Dis. 2016 Sep 15;63(6):836-843. doi: 10.1093/cid/ciw382. Epub 2016 Jun 15.

20.

HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing.

Rhee SY, Jordan MR, Raizes E, Chua A, Parkin N, Kantor R, Van Zyl GU, Mukui I, Hosseinipour MC, Frenkel LM, Ndembi N, Hamers RL, Rinke de Wit TF, Wallis CL, Gupta RK, Fokam J, Zeh C, Schapiro JM, Carmona S, Katzenstein D, Tang M, Aghokeng AF, De Oliveira T, Wensing AM, Gallant JE, Wainberg MA, Richman DD, Fitzgibbon JE, Schito M, Bertagnolio S, Yang C, Shafer RW.

PLoS One. 2015 Dec 30;10(12):e0145772. doi: 10.1371/journal.pone.0145772. eCollection 2015.

21.

Sustainable HIV treatment in Africa through viral-load-informed differentiated care.

Working Group on Modelling of Antiretroviral Therapy Monitoring Strategies in Sub-Saharan Africa, Phillips A, Shroufi A, Vojnov L, Cohn J, Roberts T, Ellman T, Bonner K, Rousseau C, Garnett G, Cambiano V, Nakagawa F, Ford D, Bansi-Matharu L, Miners A, Lundgren JD, Eaton JW, Parkes-Ratanshi R, Katz Z, Maman D, Ford N, Vitoria M, Doherty M, Dowdy D, Nichols B, Murtagh M, Wareham M, Palamountain KM, Chakanyuka Musanhu C, Stevens W, Katzenstein D, Ciaranello A, Barnabas R, Braithwaite RS, Bendavid E, Nathoo KJ, van de Vijver D, Wilson DP, Holmes C, Bershteyn A, Walker S, Raizes E, Jani I, Nelson LJ, Peeling R, Terris-Prestholt F, Murungu J, Mutasa-Apollo T, Hallett TB, Revill P.

Nature. 2015 Dec 3;528(7580):S68-76. doi: 10.1038/nature16046.

22.

Editorial Commentary: Scaling Up Antiretroviral Therapy in Africa: Are We There Yet?

Manasa J, Katzenstein D.

Clin Infect Dis. 2016 Feb 15;62(4):519-20. doi: 10.1093/cid/civ931. Epub 2015 Nov 10. No abstract available.

PMID:
26561533
23.

Phenotype, Genotype, and Drug Resistance in Subtype C HIV-1 Infection.

Derache A, Wallis CL, Vardhanabhuti S, Bartlett J, Kumarasamy N, Katzenstein D.

J Infect Dis. 2016 Jan 15;213(2):250-6. doi: 10.1093/infdis/jiv383. Epub 2015 Jul 14.

24.

Correction: Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis.

Rhee SY, Blanco JL, Jordan MR, Taylor J, Lemey P, Varghese V, Hamers RL, Bertagnolio S, de Wit TF, Aghokeng AF, Albert J, Avi R, Avila-Rios S, Bessong PO, Brooks JI, Boucher CA, Brumme ZL, Busch MP, Bussmann H, Chaix ML, Chin BS, D'Aquin TT, De Gascun CF, Derache A, Descamps D, Deshpande AK, Djoko CF, Eshleman SH, Fleury H, Frange P, Fujisaki S, Harrigan PR, Hattori J, Holguin A, Hunt GM, Ichimura H, Kaleebu P, Katzenstein D, Kiertiburanakul S, Kim JH, Kim SS, Li Y, Lutsar I, Morris L, Ndembi N, Kee PN, Paranjape RS, Peeters M, Poljak M, Price MA, Ragonnet-Cronin ML, Reyes-Terán G, Rolland M, Sirivichayakul S, Smith DM, Soares MA, Soriano VV, Ssemwanga D, Stanojevic M, Stefani MA, Sugiura W, Sungkanuparph S, Tanuri A, Tee KK, Truong HM, van de Vijver DA, Vidal N, Yang C, Yang R, Yebra G, Ioannidis JP, Vandamme AM, Shafer RW.

PLoS Med. 2015 Jun 1;12(6):e1001845. doi: 10.1371/journal.pmed.1001845. eCollection 2015 Jun. No abstract available.

25.

Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis.

Rhee SY, Blanco JL, Jordan MR, Taylor J, Lemey P, Varghese V, Hamers RL, Bertagnolio S, Rinke de Wit TF, Aghokeng AF, Albert J, Avi R, Avila-Rios S, Bessong PO, Brooks JI, Boucher CA, Brumme ZL, Busch MP, Bussmann H, Chaix ML, Chin BS, D'Aquin TT, De Gascun CF, Derache A, Descamps D, Deshpande AK, Djoko CF, Eshleman SH, Fleury H, Frange P, Fujisaki S, Harrigan PR, Hattori J, Holguin A, Hunt GM, Ichimura H, Kaleebu P, Katzenstein D, Kiertiburanakul S, Kim JH, Kim SS, Li Y, Lutsar I, Morris L, Ndembi N, Ng KP, Paranjape RS, Peeters M, Poljak M, Price MA, Ragonnet-Cronin ML, Reyes-Terán G, Rolland M, Sirivichayakul S, Smith DM, Soares MA, Soriano VV, Ssemwanga D, Stanojevic M, Stefani MA, Sugiura W, Sungkanuparph S, Tanuri A, Tee KK, Truong HM, van de Vijver DA, Vidal N, Yang C, Yang R, Yebra G, Ioannidis JP, Vandamme AM, Shafer RW.

PLoS Med. 2015 Apr 7;12(4):e1001810. doi: 10.1371/journal.pmed.1001810. eCollection 2015 Apr. Erratum in: PLoS Med. 2015 Jun;12(6):e1001845.

26.

Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230.

Kumarasamy N, Aga E, Ribaudo HJ, Wallis CL, Katzenstein DA, Stevens WS, Norton MR, Klingman KL, Hosseinipour MC, Crump JA, Supparatpinyo K, Badal-Faesen S, Bartlett JA.

Clin Infect Dis. 2015 May 15;60(10):1552-8. doi: 10.1093/cid/civ109. Epub 2015 Feb 18.

27.

HIV drug resistance mutations in proviral DNA from a community treatment program.

Derache A, Shin HS, Balamane M, White E, Israelski D, Klausner JD, Freeman AH, Katzenstein D.

PLoS One. 2015 Jan 30;10(1):e0117430. doi: 10.1371/journal.pone.0117430. eCollection 2015.

28.

The cryptococcal antigen lateral flow assay: A point-of-care diagnostic at an opportune time.

Tang MW, Clemons KV, Katzenstein DA, Stevens DA.

Crit Rev Microbiol. 2016 Aug;42(4):634-42. doi: 10.3109/1040841X.2014.982509. Epub 2015 Jan 23. Review.

PMID:
25612826
29.

Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors.

Basson AE, Rhee SY, Parry CM, El-Khatib Z, Charalambous S, De Oliveira T, Pillay D, Hoffmann C, Katzenstein D, Shafer RW, Morris L.

Antimicrob Agents Chemother. 2015 Feb;59(2):960-71. doi: 10.1128/AAC.04215-14. Epub 2014 Nov 24.

30.

HIV diversity and drug resistance from plasma and non-plasma analytes in a large treatment programme in western Kenya.

Kantor R, DeLong A, Balamane M, Schreier L, Lloyd RM Jr, Injera W, Kamle L, Mambo F, Muyonga S, Katzenstein D, Hogan J, Buziba N, Diero L.

J Int AIDS Soc. 2014 Nov 18;17:19262. doi: 10.7448/IAS.17.1.19262. eCollection 2014.

31.

Drug resistance mutations from whole blood proviral DNA among patients on antiretroviral drugs in Zimbabwe.

Chimukangara B, Gwanzura L, Mitchell R, Katzenstein D, Masimirembwa C.

Curr HIV Res. 2014;12(5):309-16.

PMID:
25323793
32.

Role of oral candidiasis in TB and HIV co-infection: AIDS Clinical Trial Group Protocol A5253.

Shiboski CH, Chen H, Ghannoum MA, Komarow L, Evans S, Mukherjee PK, Isham N, Katzenstein D, Asmelash A, Omozoarhe AE, Gengiah S, Allen R, Tripathy S, Swindells S; AIDS Clinical Trials Group Network and Oral HIV/AIDS Research Alliance.

Int J Tuberc Lung Dis. 2014 Jun;18(6):682-8. doi: 10.5588/ijtld.13.0729.

33.

Association between latent proviral characteristics and immune activation in antiretrovirus-treated human immunodeficiency virus type 1-infected adults.

Liang EC, Sceats L, Bayless NL, Strauss-Albee DM, Kubo J, Grant PM, Furman D, Desai M, Katzenstein DA, Davis MM, Zolopa AR, Blish CA.

J Virol. 2014 Aug;88(15):8629-39. doi: 10.1128/JVI.01257-14. Epub 2014 May 21.

34.

Drug susceptibility and resistance mutations after first-line failure in resource limited settings.

Wallis CL, Aga E, Ribaudo H, Saravanan S, Norton M, Stevens W, Kumarasamy N, Bartlett J, Katzenstein D; A5230 team.

Clin Infect Dis. 2014 Sep 1;59(5):706-15. doi: 10.1093/cid/ciu314. Epub 2014 May 1.

35.

An affordable HIV-1 drug resistance monitoring method for resource limited settings.

Manasa J, Danaviah S, Pillay S, Padayachee P, Mthiyane H, Mkhize C, Lessells RJ, Seebregts C, de Wit TF, Viljoen J, Katzenstein D, De Oliveira T.

J Vis Exp. 2014 Mar 30;(85). doi: 10.3791/51242.

36.

HIV-1 RNA levels and antiretroviral drug resistance in blood and non-blood compartments from HIV-1-infected men and women enrolled in AIDS clinical trials group study A5077.

Kantor R, Bettendorf D, Bosch RJ, Mann M, Katzenstein D, Cu-Uvin S, D'Aquila R, Frenkel L, Fiscus S, Coombs R; ACTG A5077 Study Team.

PLoS One. 2014 Apr 3;9(4):e93537. doi: 10.1371/journal.pone.0093537. eCollection 2014.

37.

Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202.

Grant PM, Tierney C, Budhathoki C, Daar ES, Sax PE, Collier AC, Fischl MA, Zolopa AR, Balamane M, Katzenstein D.

HIV Clin Trials. 2013 Nov-Dec;14(6):284-91. doi: 10.1310/hct1406-284.

38.

Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine.

Smith KY, Tierney C, Mollan K, Venuto CS, Budhathoki C, Ma Q, Morse GD, Sax P, Katzenstein D, Godfrey C, Fischl M, Daar ES, Collier AC; AIDS Clinical Trials Group 5202 Study Team.

Clin Infect Dis. 2014 Feb;58(4):555-63. doi: 10.1093/cid/cit747. Epub 2013 Nov 18.

39.

HIV RNA and genotype in resource-limited settings: can we do better?

Katzenstein DA.

Clin Infect Dis. 2014 Jan;58(1):110-2. doi: 10.1093/cid/cit634. Epub 2013 Sep 27. No abstract available.

PMID:
24076967
40.

Capacity building and predictors of success for HIV-1 drug resistance testing in the Asia-Pacific region and Africa.

Land S, Zhou J, Cunningham P, Sohn AH, Singtoroj T, Katzenstein D, Mann M, Sayer D, Kantor R.

J Int AIDS Soc. 2013 Jul 10;16:18580. doi: 10.7448/IAS.16.1.18580.

41.

Prototypical Recombinant Multi-Protease-Inhibitor-Resistant Infectious Molecular Clones of Human Immunodeficiency Virus Type 1.

Varghese V, Mitsuya Y, Fessel WJ, Liu TF, Melikian GL, Katzenstein DA, Schiffer CA, Holmes SP, Shafer RW.

Antimicrob Agents Chemother. 2013 Sep;57(9):4290-4299. doi: 10.1128/AAC.00614-13. Epub 2013 Jun 24.

42.

Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine.

Tang MW, Rhee SY, Bertagnolio S, Ford N, Holmes S, Sigaloff KC, Hamers RL, de Wit TF, Fleury HJ, Kanki PJ, Ruxrungtham K, Hawkins CA, Wallis CL, Stevens W, van Zyl GU, Manosuthi W, Hosseinipour MC, Ngo-Giang-Huong N, Belec L, Peeters M, Aghokeng A, Bunupuradah T, Burda S, Cane P, Cappelli G, Charpentier C, Dagnra AY, Deshpande AK, El-Katib Z, Eshleman SH, Fokam J, Gody JC, Katzenstein D, Koyalta DD, Kumwenda JJ, Lallemant M, Lynen L, Marconi VC, Margot NA, Moussa S, Ndung'u T, Nyambi PN, Orrell C, Schapiro JM, Schuurman R, Sirivichayakul S, Smith D, Zolfo M, Jordan MR, Shafer RW.

J Infect Dis. 2013 Jun 15;207 Suppl 2:S70-7. doi: 10.1093/infdis/jit114.

43.

In vitro HIV-1 evolution in response to triple reverse transcriptase inhibitors & in silico phenotypic analysis.

Rath BA, Yousef KP, Katzenstein DK, Shafer RW, Schütte C, von Kleist M, Merigan TC.

PLoS One. 2013 Apr 17;8(4):e61102. doi: 10.1371/journal.pone.0061102. Print 2013.

44.

Screening for pulmonary tuberculosis in HIV-infected individuals: AIDS Clinical Trials Group Protocol A5253.

Swindells S, Komarow L, Tripathy S, Cain KP, MacGregor RR, Achkar JM, Gupta A, Veloso VG, Asmelash A, Omoz-Oarhe AE, Gengiah S, Lalloo U, Allen R, Shiboski C, Andersen J, Qasba SS, Katzenstein DK; AIDS Clinical Trials Group 5253 Study Team.

Int J Tuberc Lung Dis. 2013 Apr;17(4):532-9. doi: 10.5588/ijtld.12.0737.

45.

Antiviral resistance and correlates of virologic failure in the first cohort of HIV-infected children gaining access to structured antiretroviral therapy in Lima, Peru: a cross-sectional analysis.

Rath BA, von Kleist M, Castillo ME, Kolevic L, Caballero P, Soto-Castellares G, Amedee AM, Robinson JE, Katzenstein DK, Van Dyke RB, Oberhelman RA.

BMC Infect Dis. 2013 Jan 2;13:1. doi: 10.1186/1471-2334-13-1.

46.

HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status.

Mollan K, Daar ES, Sax PE, Balamane M, Collier AC, Fischl MA, Lalama CM, Bosch RJ, Tierney C, Katzenstein D; AIDS Clinical Trials Group Study A5202 Team.

J Infect Dis. 2012 Dec 15;206(12):1920-30. doi: 10.1093/infdis/jis613. Epub 2012 Nov 12.

47.

Comparing Peripheral Blood Mononuclear Cell DNA and Circulating Plasma viral RNA pol Genotypes of Subtype C HIV-1.

Banks L, Gholamin S, White E, Zijenah L, Katzenstein DA.

J AIDS Clin Res. 2012 Feb;3(2):141-147.

48.

Are subtype differences important in HIV drug resistance?

Lessells RJ, Katzenstein DK, de Oliveira T.

Curr Opin Virol. 2012 Oct;2(5):636-43. doi: 10.1016/j.coviro.2012.08.006. Epub 2012 Sep 21. Review.

49.

Global analysis of sequence diversity within HIV-1 subtypes across geographic regions.

Huang A, Hogan JW, Istrail S, Delong A, Katzenstein DA, Kantor R.

Future Virol. 2012 May;7(5):505-517.

50.

Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine.

Balamane M, Varghese V, Melikian GL, Fessel WJ, Katzenstein DA, Shafer RW.

Antimicrob Agents Chemother. 2012 Aug;56(8):4522-4. doi: 10.1128/AAC.00648-12. Epub 2012 Jun 4.

Supplemental Content

Loading ...
Support Center